SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)

Ruszniewski, P; Caplin, M; Valle, L; Lombard-Bohas, D; Poston, G; Perros, P; Holubec, L; Delle, Pave, G; Smith, D; Niccoli, P; Maisonobe, P; Atlan, P

doi:10.1159/000367792

SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Ruszniewski P, Caplin M, Valle L, Lombard-Bohas D, Poston G, Perros P, Holubec L, Delle Pave G, Smith D, Niccoli P, Maisonobe P, Atlan P

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease

Year of Conference: 2014

Pages: 274-274

Publisher: Karger

URL: http://dx.doi.org/10.1159/000367792

DOI: 10.1159/000367792

Library holdings: Search Newcastle University Library for this item

Series Title: Neuroendocrinology

ISBN: 14230194

ePrints

SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)

Downloads

Publication metadata

Share